Edward Tobinick M.D. Scientific Publications

Selected Scientific Publications of Edward Tobinick MD and Colleagues

The following are a selected portion of the published, peer-reviewed scientific publications of Dr. Edward Tobinick. Additional scientific publications of Dr. Tobinick are available here*.

Immediate Resolution of Hemispatial Neglect and Central Post-Stroke Pain After Perispinal Etanercept: Case Report. Edward Tobinick, Clinical Drug Investigation, 2019, pp 1-5; (Free Download).
Perispinal etanercept advances as a neurotherapeutic. Tobinick, E., Expert Review Neurotherapeutics, 2018:1-3. Free Link to Journal Article.
On Overcoming Barriers to Application of Neuroinflammation Research. Tobinick E, Ignatowski, T., Spengler, R. In: Abreu GEA, ed. Mechanisms of Neuroinflammation: InTechOpen; 2017. Download free full-text PDF.
Perispinal Etanercept for Traumatic Brain Injury. Edward Tobinick, Rodriguez-Romanacce H, Kinssies R, Kim N. Chapter 7 In: Heidenreich KA, editor. New Therapeutics for Traumatic Brain Injury. Cambridge, Mass.: Academic Press; 2017. p. 109-29. LINK.
Perispinal Delivery of CNS Drugs. Edward Tobinick MD. CNS Drugs. 2016:30(6):469-80. (Download free full-text PDF)
Author’s Reply to Whitlock: Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence. Ignatowski TA, Spengler RN, Tobinick E. CNS Drugs, epub November 2014, doi: 10.1007/s40263-014-0212-0, published online 06 Nov 2014. (Download free full-text PDF)
Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence. Ignatowski TA, Spengler RN, Dhandapani KM, Folkersma H, Butterworth RF, Tobinick E. CNS Drugs, August 2014, 28(8):679-697, published online 27 May 2014. (Download free full-text PDF)
Immediate neurological recovery following perispinal etanercept years after brain injury. Tobinick E, Rodriguez-Romanacce H, Levine A, Ignatowski TA, Spengler RN. Clin Drug Investig. 2014 May;34(5):361-6.
Selective TNF Inhibition for Chronic Stroke and Traumatic Brain Injury – An Observational Study Involving 629 Consecutive Patients Treated with Perispinal Etanercept. Edward Tobinick MD, Nancy M. Kim MD, et.al. CNS Drugs. 2012 Dec;26(12):1051-70.
Deciphering the physiology underlying the rapid clinical effects of perispinal etanercept in Alzheimer’s disease. Edward Tobinick MD. Current Alzheimer Research 2012, 9:99-109. (Download free full-text PDF).
Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases. Edward Tobinick MD. CNS Drugs. 2011 Feb 1; 25(2):145-155.
Perispinal etanercept: a new therapeutic paradigm in neurology. Edward Tobinick MD. Expert Review of Neurotherapeutics. 2010 Jun;10(6):985-1002. (Download free full-text PDF).
Tumour necrosis factor modulation for treatment of Alzheimer’s disease: rationale and current evidence. Edward Tobinick MD. CNS Drugs. 2009 Sep 1;23(9):713-25.
The value of drug repositioning in the current pharmaceutical market. Edward Tobinick MD. Drug News Perspect. 2009 Mar;22(2):119-25. Review.
Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging. Edward Tobinick MD, K Chen PhD, X Chen PhD. BMC Res Notes. 2009 Feb 27;2:28.
Perispinal etanercept for neuroinflammatory disorders. Edward Tobinick MD. Drug Discovery Today. 2009 Feb;14(3-4):168-77.
Perispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism. Edward Tobinick MD. Medscape J Med. 2008 Jun 10;10(6):135.
Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer’s disease. Edward Tobinick MD, H. Gross MD. BMC Neurology. 2008 Jul 21;8:27.
Re: Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Edward Tobinick MD. Neurology. 2008 Apr 1;70(14):1222-3.
Perispinal etanercept for treatment of Alzheimer’s disease. Edward Tobinick MD. Current Alzheimer Research. 2007 Dec;4(5):550-2.
A critique of intradiscal administration for treatment of radiculopathy. Edward Tobinick MD. Anesthesiology. 2008 Feb;108(2):334.
Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. Edward Tobinick MD, Hyman Gross MD. Journal of Neuroinflammation. 2008 Jan 9;5:2. (Download free full-text PDF)
Spinal delivery of p38: TNF-alpha inhibitors. E Tobinick MD. PLoS Med. 2006 Nov;3(11):e511.
TNF-alpha modulation for treatment of Alzheimer’s disease: a 6-month pilot study. Edward Tobinick MD, Hyman Gross MD, Alan Weinberger MD, Hart Cohen MD. MedGenMed. 2006 Apr 26;8(2):25.
The cerebrospinal venous system: anatomy, physiology, and clinical implications. Edward Tobinick MD. MedGenMed. 2006 Feb 22;8(1):53.
Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients. Edward Tobinick MD, Susan Davoodifar MD. Curr Med Res Opin. 2004 Jul;20(7):1075-85.
Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports. Edward L. Tobinick MD. Clinical Therapeutics. 2003 Aug;25(8):2279-88.

Please see the following publications by scientists independent of the INR for additional scientific background:

Batson OV. The vertebral vein system. Caldwell lecture, 1956. Am J Roentgenol Radium Ther Nucl Med. 1957;78(2):195-212.
Pearce JM. The craniospinal venous system. Eur Neurol. 2006;56(2):136-8.
Nathoo N, Caris EC, Wiener JA, Mendel E. History of the vertebral venous plexus and the significant contributions of Breschet and Batson. Neurosurgery. 2011;69(5):1007-14; discussion 14.
Griessenauer CJ, Raborn J, Foreman P, Shoja MM, Loukas M, Tubbs RS. Venous Drainage of the Spine and Spinal Cord: A Comprehensive Review of its History, Embryology, Anatomy, Physiology, and Pathology. Clinical Anatomy. 2014;epub.
Randomized, Double-blind, Placebo-Controlled, Trial of Transforaminal Epidural Etanercept for the Treatment of Symptomatic Lumbar Disc Herniation. Spine (Phila Pa 1976), 2013. 38(23): p. 1986-94. Freeman, B.J., et. al.
Epidural administration of spinal nerves with the tumor necrosis factor-alpha inhibitor, etanercept, compared with dexamethasone for treatment of sciatica in patients with lumbar spinal stenosis: a prospective randomized study. Spine (Phila Pa 1976), 2012. 37(6): p. 439-44. Ohtori, et. al.

Therapeutic evaluation of etanercept in a model of traumatic brain injury.Chio CC, Lin JW, Chang MW, Wang CC, Kuo JR, Yang CZ, Chang CP. J Neurochem. 2010 Nov;115(4):921-9.
Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases. Frankola KA, Greig NH, Luo W, Tweedie D. CNS Neurol Disord Drug Targets. 2011 Feb 2.
Anti-TNF therapy in the injured spinal cord. Esposito E, Cuzzocrea S. Trends Pharmacol Sci. 2011 Feb;32(2):107-15. Epub 2010 Dec 23.
Etanercept restores the antinociceptive effect of morphine and suppresses spinal neuroinflammation in morphine-tolerant rats. Shen CH, Tsai RY, Shih MS, Lin SL, Tai YH, Chien CC, Wong CS. Anesth Analg. 2011 Feb;112(2):454-9.
Anti-TNF-alpha reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Shi JQ, Shen W, Chen J, Wang BR, Zhong LL, Zhu YW, Zhu HQ, Zhang QQ, Zhang YD, Xu J. Brain Res. 2011 Jan 12;1368:239-47.
Attenuation of Inflammatory Events in Human Intervertebral Disc Cells with a Tumor Necrosis Factor Antagonist. Sinclair SM, Shamji MF, Chen J, Jing L, Richardson WJ, Brown CR, Fitch RD, Setton LA. Spine (Phila Pa 1976). 2011 Jan 6.
Intrathecal inflammation precedes development of Alzheimer’s disease. Tarkowski E, Andreasen N, Tarkowski A, Blennow K. J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1200-5.
Perispinal etanercept: potential as an Alzheimer therapeutic.Griffin WS. J Neuroinflammation. 2008 Jan 10;5:3. (Download free full-text PDF).
Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Park KM, Bowers WJ. Cell Signal. 2010 Jul;22(7):977-83.
The roles of TNF in brain dysfunction and disease. Clark IA, Alleva LM, Vissel B. Pharmacol Ther. 2010 Dec;128(3):519-48.
An association study of 21 potential Alzheimer’s disease risk genes in a Finnish population. Sarajärvi T, Helisalmi S, Antikainen L, Mäkinen P, Koivisto AM, Herukka SK, Haapasalo A, Soininen H, Hiltunen M. J Alzheimers Dis. 2010;21(3):763-7.
The role of TNF-alpha signaling pathway on COX-2 upregulation and cognitive decline induced by beta-amyloid peptide. Medeiros R, Figueiredo CP, Pandolfo P, Duarte FS, Prediger RD, Passos GF, Calixto JB. Behav Brain Res. 2010 May 1;209(1):165-73.
Soluble TNF receptors are associated with A? metabolism and conversion to dementia in subjects with mild cognitive impairment. Buchhave P, Zetterberg H, Blennow K, Minthon L, Janciauskiene S, Hansson O. Neurobiol Aging. 2010 Nov;31(11):1877-84.
Inflammation and anti-inflammatory strategies for Alzheimer’s disease–a mini-review. McNaull BB, Todd S, McGuinness B, Passmore AP. Gerontology. 2010;56(1):3-14.
Systemic inflammation and disease progression in Alzheimer disease. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, Culliford D, Perry VH. Neurology. 2009 Sep 8;73(10):768-74.
Paths to acceptance. The advancement of scientific knowledge is an uphill struggle against ‘accepted wisdom’. Wolinsky H. EMBO Rep. 2008 May;9(5):416-8.

About Dr. Tobinick

Edward Lewis Tobinick is an American physician who is the inventor of new methods of treatment of neurological disorders. Dr. Tobinick graduated Phi Beta Kappa and Magna Cum Laude with honors in biology from Brandeis University in Waltham, Massachusetts and received his M.D. from the University of California San Diego School of Medicine in La Jolla, California.

The published scientific articles documenting unprecedented neurological effects produced by the novel method of drug delivery invented by Dr. Tobinick have been cited by hundreds of scientists from academic centers around the world.

Dr. Tobinick's breakthrough stroke treatment has been used to treat patients from every continent in the world, including from the U.S., Canada, England, Scotland, Wales, Ireland, Mexico, Trinidad, Jamaica, Haiti, Bahamas, Guatemala, Belize, Brazil, Columbia, Bolivia, Uruguay, Ecuador, Chile, Peru, Germany, France, Spain, Italy, Portugal, Belgium, Netherlands, Switzerland, Bulgaria, Romania, Ukraine, Poland, Denmark, Sweden, Norway, Iceland, Gibraltar, Uzbekistan, Turkey, Israel, Saudi Arabia, UAE, Oman, Iraq, Egypt, Morocco, Nigeria, Ghana, Cameroon, South Africa, Mozambique, Kenya, Mauritius, India, Bangladesh, Thailand, Vietnam, China, Hong Kong, Japan, Indonesia, Malaysia, Philippines, Australia, New Zealand, Papua New Guinea, Fiji, and the Cook Islands.

In 2018 the Australian Minister of Health, Hon. Greg Hunt, designated substantial funds to study Dr. Tobinick's breakthrough stroke treatment in Australia.

Dr. Tobinick has been an invited ad hoc reviewer for the journals Brain Research, Clinical Drug Investigation, CNS Drugs, Current Alzheimer Research, Experimental Neurology, Future Neurology, Journal of Neurochemistry, Journal of Neuroimmunology, Neuroscience, and Pharmaceutical Medicine and a member of the Editorial Board of the Journal of Neuroinflammation.

More Info